Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Chimeric Therapeutics - European patent granted for CLTX technology used in CHM 1101 (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company, is pleased to announce the European Patent Office’s decision to gra...read more

Chimeric Therapeutics - Partnership with OncoBay Clinical to advance CHM 1101 (ASX:CHM)

-- Chimeric and OncoBay Clinical have entered into a strategic partnership to advance and expand the development program for CHM 1101 (CLTX CAR T) -- OncoBay Clinical is a boutique clinical researc...read more

Chimeric Therapeutics - Initial Director's Interest Notice - JC (ASX:CHM)

To view the Initial Director’s Interest Notice, download the attached PDF.

Chimeric Therapeutics - Preliminary Final Report (ASX:CHM)

Distributions No dividends have been paid or declared by the company for the current financial period. No dividends were paid for the previous financial period. Explanation of results The g...read more

Chimeric Therapeutics Appoints Jennifer Chow as CEO & MD (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company, is pleased to announce the appointment of current Chief Operating Officer...read more

Chimeric Therapeutics - IND clearance received from US FDA for CHM 1101 (ASX:CHM)

First IND clearance received from US FDA for CHM 1101 (CLTX CAR T) for patients with recurrent and progressive Glioblastoma Provides the foundation for advancing development of CHM 1101 Enables...read more

Chimeric Therapeutics licenses novel solid tumor CAR T therapy from Penn (ASX:CHM)

-- Chimeric has obtained the exclusive license to a novel CAR T for solid tumors from the University of Pennsylvania (Penn) -- The CDH17 CAR T has demonstrated the complete eradication of tumor cel...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Chimeric Therapeutics Limited (“the Company”) (ASX: CHM), a clinical stage cell therapy company, is pleased to provide a summary of its activities for the quarter ended 30 June 2021. ...read more

CYC First Half Trading Update (ASX:CYC)

Cyclopharm Limited (ASX: CYC) is pleased to provide the following update on its trading performance for first half of 2021. Following a review of the company’s unaudited management accounts...read more

Cyclopharm USFDA Update (ASX:CYC)

Cyclopharm Limited (ASX: CYC) announcesthat the US Food and Drug Administration (USFDA) has provided a Complete Response Letter (CRL) for the New Drug Application (NDA) for TechnegasTM. The USFDA ha...read more

Chimeric Therapeutics - Second Dose Cohort Initiated in CLTX CAR T Phase 1 Trial (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company, is pleased to announce the treatment of the first patient in the second d...read more

Cyclopharm Amended Constitution (ASX:CYC)

Please find attached CYC’s Amended Constitution adopted by special resolution at today’s Annual General Meeting. For more information, download the attached PDF.

Cyclopharm - Results of Meeting (ASX:CYC)

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution in the attached voting r...read more

Cyclopharm - Becoming a substantial holder from MUFG (ASX:CYC)

To view the notice of initial substantial holder, download the attached PDF.

Cyclopharm - Ceasing to be a substantial holder from MUFG (ASX:CYC)

To view the notice of ceasing to be a substantial holder, download the attached PDF.

Viewing: 76 - 90 of 154 Previous | Next